QbD more likely in generics than brand drugs; World Courier expands trial supply network;

> Generics makers have a greater probability designing processes that follow the Quality by Design regimen and using continuous processes for their manufacturing versus brand companies. Article

> World Courier says it will expand its GMP-compliant clinical trial supply chain services network to 13 strategic and emerging markets; among them is Singapore, now home to a 135,000-square-foot distribution facility. World Courier release

> Indian pharma Shilpa Medicare said it has received European Union GMP approval from Germany for two of its manufacturing sites for production of cancer drugs. Item

> Visible particle contamination has driven Lundbeck to a voluntary recall of two lots of NeoProfen (ibuprofen lysine) injection. Lundbeck release

> U.K. contract manufacturer and fill/finish specialist SCM Pharma has launched two services: sterility testing, and bacterial endotoxin testing. SCM Pharma release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.